[go: up one dir, main page]

MX2021008017A - Formulaciones de colagenasa y metodos de produccion de las mismas. - Google Patents

Formulaciones de colagenasa y metodos de produccion de las mismas.

Info

Publication number
MX2021008017A
MX2021008017A MX2021008017A MX2021008017A MX2021008017A MX 2021008017 A MX2021008017 A MX 2021008017A MX 2021008017 A MX2021008017 A MX 2021008017A MX 2021008017 A MX2021008017 A MX 2021008017A MX 2021008017 A MX2021008017 A MX 2021008017A
Authority
MX
Mexico
Prior art keywords
methods
collagenase
formulations
production
collagenase formulations
Prior art date
Application number
MX2021008017A
Other languages
English (en)
Inventor
Karunakar Sukuru
Original Assignee
Endo Global Aesthetics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endo Global Aesthetics Ltd filed Critical Endo Global Aesthetics Ltd
Publication of MX2021008017A publication Critical patent/MX2021008017A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24003—Microbial collagenase (3.4.24.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

En el presente documento se describen formulaciones mejoradas que contienen colagenasa y métodos para preparar las mismas. Las formulaciones que contienen colagenasa comprenden una colagenasa, de aproximadamente 30 mM a aproximadamente 240 mM de un disacárido, de aproximadamente 50 mM a aproximadamente 800 mM de manitol y de aproximadamente 6 mM a aproximadamente 10 mM de un HCl de Tris. También se proporcionan formulaciones liofilizadas y reconstituidas.
MX2021008017A 2019-01-06 2020-01-03 Formulaciones de colagenasa y metodos de produccion de las mismas. MX2021008017A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962788916P 2019-01-06 2019-01-06
PCT/US2020/012202 WO2020142701A1 (en) 2019-01-06 2020-01-03 Collagenase formulations and methods of producing the same

Publications (1)

Publication Number Publication Date
MX2021008017A true MX2021008017A (es) 2021-08-05

Family

ID=69845512

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008017A MX2021008017A (es) 2019-01-06 2020-01-03 Formulaciones de colagenasa y metodos de produccion de las mismas.

Country Status (10)

Country Link
US (3) US20220305094A1 (es)
EP (1) EP3906014A1 (es)
JP (2) JP7565280B2 (es)
KR (1) KR20210113271A (es)
CN (1) CN113382714A (es)
AU (2) AU2020204922B2 (es)
BR (1) BR112021012675A2 (es)
IL (2) IL321891A (es)
MX (1) MX2021008017A (es)
WO (1) WO2020142701A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112941058B (zh) * 2021-04-02 2023-12-05 重庆科润生物医药研发有限公司 一种重组溶组织梭菌ii型胶原酶及其制备方法和应用
CN113025599B (zh) * 2021-04-02 2023-09-12 重庆科润生物医药研发有限公司 一种重组溶组织梭菌i型胶原酶及其制备方法和应用
CN114264633B (zh) * 2022-02-10 2022-09-06 上海蓝长科技集团有限公司 一种福尔马肼聚合物冻干粉及制备方法
JP2025509284A (ja) * 2022-03-08 2025-04-11 コネクスト カンパニー リミテッド コラゲナーゼ、カルシウム、ヒスチジン及びグリシンを含む組成物及びコラゲナーゼの安定化方法
CN119656117B (zh) * 2024-12-18 2025-08-29 远大生命科学(鞍山)有限公司 一种药物组合物及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1820516E (pt) 1999-02-22 2013-10-31 Baxter Int Novas formulações de factor viii isentas de albumina
US6440414B1 (en) * 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US20070237758A1 (en) * 2005-11-22 2007-10-11 Anthony Barry Immunoglobulin fusion protein formulations
US7811560B2 (en) 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
ES2388219T3 (es) * 2008-06-02 2012-10-10 F. Hoffmann-La Roche Ag Purificación mejorada de colagenasas a partir de un cultivo líquido de Clostridium histolyticum
US10119131B2 (en) 2011-03-16 2018-11-06 Biospecifics Technologies Corp. Compositions and methods for producing clostridial collagenases
AU2012325941A1 (en) * 2011-10-21 2014-05-15 Auxilium International Holdings, Inc. Method of treating or reducing EFP
PT3584317T (pt) 2012-01-12 2022-01-26 Endo Global Ventures Enzima de clostridium histolyticum
US9744138B2 (en) 2013-03-15 2017-08-29 Biospecifics Technologies Corp. Treatment method and product for uterine fibroids using purified collagenase
US10137179B2 (en) * 2016-05-18 2018-11-27 Hyalo Technologies, LLC Composition and method of preparation of protease microparticulate slow release preparation
WO2018068012A1 (en) * 2016-10-07 2018-04-12 Regeneron Pharmaceuticals, Inc. Room temperature stable lyophilized protein
PT3589204T (pt) * 2017-03-01 2025-07-18 Endo Operations Ltd Aparelho e método de avaliação e tratamento da celulite

Also Published As

Publication number Publication date
BR112021012675A2 (pt) 2021-09-28
IL284270B2 (en) 2025-12-01
JP2025016453A (ja) 2025-02-04
JP7565280B2 (ja) 2024-10-10
US12303557B2 (en) 2025-05-20
AU2020204922A1 (en) 2021-07-01
CA3125007A1 (en) 2020-07-09
KR20210113271A (ko) 2021-09-15
EP3906014A1 (en) 2021-11-10
US20220305094A1 (en) 2022-09-29
IL284270B1 (en) 2025-08-01
JP2022516569A (ja) 2022-02-28
IL284270A (en) 2021-08-31
CN113382714A (zh) 2021-09-10
AU2020204922B2 (en) 2025-04-24
WO2020142701A1 (en) 2020-07-09
US20250249080A1 (en) 2025-08-07
US20240041993A1 (en) 2024-02-08
AU2025204915A1 (en) 2025-07-24
IL321891A (en) 2025-09-01

Similar Documents

Publication Publication Date Title
MX2021008017A (es) Formulaciones de colagenasa y metodos de produccion de las mismas.
CO2019012893A2 (es) Composiciones farmacéuticas de atropina
UY37563A (es) Aislados de bacillus y usos de los mismos
CO2018005361A2 (es) Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
AR120534A1 (es) Aislados paenibacillus y sus usos
CO2019009258A2 (es) Administración rápida y controlada de composiciones con efectos séquito restaurados
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
DOP2018000257A (es) Piridinas sustituidas con heteroarilo y métodos de uso
UY37564A (es) Aislados de lysinibacillus y usos de los mismos
DOP2016000287A (es) Composiciones y métodos para modular la expresión de ttr y vh
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
MX2018005925A (es) Purinonas como inhibidores de proteasa específica de ubiquitina 1.
MX2017011269A (es) Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
MX2019015877A (es) Método para mejorar el rendimiento o la calidad de los cultivos.
MX2016006488A (es) Formulacion liofilizada de conjugado de anticuerpo-farmaco.
PE20181334A1 (es) Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
MX2012011504A (es) Inhibidores de enzima 1 dependiente de inositol (ire-1 alfa).
MX2021000328A (es) Enzimas de variantes de galactosa oxidasa modificadas geneticamente.
CL2011003003A1 (es) Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria.
MX385109B (es) Formulaciones de anticuerpos.
EA202190331A1 (ru) Композиции терапевтически активных частиц с модифицированной поверхностью, полученные путем ультрабыстрой заморозки
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
BR112017005231A2 (pt) formulações eutéticas de cloridrato de ciclobenzaprina